The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

STEMI Clinical Trial

Official title:

The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05043558
• Other study ID #: LHD Beraprost sodium
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 1, 2022
• Est. completion date: January 12, 2022

Study information

• Verified date: August 2021
• Source: Shenzhen People's Hospital
• Contact: Huadong Liu, doctor
• Phone: 13724397998
• Email: lhd2578[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the protective effect of prostaglandin sodium on coronary microcirculation function and ventricular remodeling after reperfusion treatment of acute ST-segment elevation myocardial infarction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 220
• Est. completion date: January 12, 2022
• Est. primary completion date: January 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• 1) Meet the diagnostic criteria for acute ST-segment elevation myocardial infarction:

?The onset of ischemic chest pain lasts for more than 30 minutes and cannot be relieved by taking nitroglycerin; ?The ECG has two or more ST-segment elevations in adjacent leads , Limb leads = 1mm, pectoral leads = 2mm; or newly-appearing left bundle branch block; ?The increase in serum markers of myocardial necrosis is at least twice the normal value; (2) Coronary angiography confirmed acute myocardial infarction; (3) Direct PCI treatment within 12 hours of onset; (4) Complete clinical and radiographic data.

Exclusion Criteria:

• (1) Those who do not cooperate in the inspection, have poor compliance, and cannot guarantee the completion of the test; (2) Persons with consciousness impairment, obvious intellectual impairment and mental abnormality; (3) With metal foreign bodies, such as metal prostheses, intraocular metal foreign bodies, intracranial aneurysm clamps, etc.; (4) Those who suffer from closure phobia; (5) Those who have had a history of myocardial infarction, PCI treatment, or coronary artery bypass graft; (6) Factors affecting the changes in the ST segment of the electrocardiogram: complete left bundle branch block, pre-excitation syndrome, pacemaker electrocardiogram

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction
• STEMI
• Ventricular Remodeling

Intervention

Drug:
• beprostaglandin sodium
beprostaglandin sodium

Locations

Country	Name	City	State
China	Shenzhen People' S Hospital	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ultrasound and CMR to assess the characteristics of myocardial infarction	Q-LAB Scale Scale calculation score	3 years